AEM Launches WMO-Compliant Automated Weather Station to Elevate Global Weather Monitoring
AEM, the essential source for environmental insights, today announced its WMO-compliant AEM Apex Automated Weather Station (AWS). This state-of-the-art solution sets a new benchmark for precision, reliability, and durability, meeting the strict standards of the World Meteorological Organization (WMO).
Designed to address the toughest challenges in weather monitoring, the WMO-compliant AWS offers unparalleled accuracy and performance for a variety of critical applications, from localized climate research to large-scale weather networks.
Key Benefits of the WMO-Compliant AWS
- Precision Data for Better Decisions: Provides WMO-compliant measurements with strict tolerances to support critical applications.
- Seamless Global Collaboration: Enables efficient data sharing with regional and global partners, fostering enhanced coordination for monitoring and forecasting.
- Reliability in Extreme Conditions: Built to deliver continuous, accurate data with minimal maintenance, even in the most demanding environments.
- Future-Proof Design: A scalable, standards-compliant system that evolves with the changing needs of users.
Advanced Specifications
The AEM Apex AWS incorporates cutting-edge components and technology, including:
- Wind Monitoring: Ultrasonic sensors with wind direction accuracy of < 2° and wind speed accuracy of ± 0.2 m/s.
- Rain Measurement: Precision load cell technology with accuracy of ± 0.1 mm or 1% at lower rainfall rates.
- Solar Monitoring: Secondary standard pyranometer for high-quality solar radiation data.
- Temperature, Humidity, and Pressure Monitoring: Air temperature accuracy up to ± 0.1 K and barometric pressure accuracy of ± 0.15 hPa.
- Communication Capabilities: Ser[LOG] data logger with 4G modem, TLS 1.3 security, and versatile communication protocols like Modbus, Ethernet, and SMS.
Serving Diverse Markets Across the Public and Private Sector
The WMO- and ICAO- (International Civil Aviation Organization) compliant AWS serves markets across weather monitoring and forecasting. National Meteorological and Hydrological Services can enhance their national weather networks with precise, reliable solutions. Regional Mesonets and research institutions will improve their local forecasting and climate monitoring capabilities, while private sector organizations in aviation, energy, and utilities can optimize operations, ensure safety, and make data-driven decisions using the most precise weather data available.
AEM’s Commitment to Weather Monitoring Excellence
AEM continues to set the standard in weather and environmental monitoring by offering end-to-end solutions, from network design and installation to software and maintenance. Trusted by government agencies, meteorological services, and communities worldwide, AEM has deployed thousands of systems for severe weather, wildfire, and flood risk management.
The AEM Apex AWS integrates seamlessly with AEM’s Elements® 360, a powerful decision-support application designed to unify and simplify data sharing, enhance response coordination, and ensure the safety of communities worldwide.
To learn more about AEM’s WMO-compliant Automated Weather Station and broader weather monitoring solutions, visit https://aem.eco.
About AEM
AEM is combining global technology leaders to empower communities and organizations to survive and thrive in the face of escalating environmental risks. By deploying intelligent sensing networks, operating a secure and scalable data management infrastructure, and delivering high-value analytics through a suite of end-user applications, AEM serves as the essential source for environmental insights. These technologies enable positive outcomes, helping reduce environmental impact and creating a safer world. For more information, visit https://aem.eco/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113755485/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom